Role of cyclic AMP sensor Epac1 in masseter muscle hypertrophy and myosin heavy chain transition induced by β2-adrenoceptor stimulation

Journal of Physiology

Volumn 592, Issue 24, 2014, Pages 5461-5475

  Ohnuki, Yoshiki ^a   Umeki, Daisuke ^a   Mototani, Yasumasa ^a   Jin, Huiling ^b   Cai, Wenqian ^b   Shiozawa, Kouichi ^a   Suita, Kenji ^b   Saeki, Yasutake ^a   Fujita, Takayuki ^b   Ishikawa, Yoshihiro ^b   Okumura, Satoshi ^a,b  

^a TSURUMI UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPORTER; BETA 2 ADRENERGIC RECEPTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CLENBUTEROL; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE 4; INITIATION FACTOR 4E BINDING PROTEIN 1; MYOSIN HEAVY CHAIN; PROTEIN EPAC1; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; EPAC PROTEIN, MOUSE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HDAC5 PROTEIN, MOUSE; HISTONE DEACETYLASE; ISOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; MASSETER MUSCLE; MOUSE; MUSCLE HYPERTROPHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CBA MOUSE; DRUG EFFECTS; GENETICS; HYPERTROPHY; METABOLISM; PATHOLOGY;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HISTONE DEACETYLASES; HYPERTROPHY; MASSETER MUSCLE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MYOSIN HEAVY CHAINS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84916618599     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2014.282996     Document Type: Article

References (58)

1. Altarejos JY & Montminy M (2011). CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Cell Biol 12, 141-151.
2. Arai C, Ohnuki Y, Umeki D & Saeki Y (2005). Effects of bite-opening and cyclosporin A on the mRNA levels of myosin heavy chain and the muscle mass in rat masseter. Jpn J Physiol 55, 173-179.
3. Bai Y, Tsunematsu T, Jiao Q, Ohnuki Y, Mototani Y, Shiozawa K, Jin M, Cai W, Jin HL, Fujita T, Ichikawa Y, Suita K, Kurotani R, Yokoyama U, Sato M, Iwatsubo K, Ishikawa Y & Okumura S (2012). Pharmacological stimulation of type 5 adenylyl cyclase stabilizes heart rate under both microgravity and hypergravity induced by parabolic flight. J Pharmacol Sci 119, 381-389.
4. 2-adrenoceptor coupling to endothelial NO synthase in mouse pulmonary artery. Cell Signal 23, 1136-1143.
5. 2B receptor blockade mediated anti-hypertrophic effect in rats. FEBS Lett 586, 180-185.
6. Brennesvik EO, Ktori C, Ruzzin J, Jebens E, Shepherd PR & Jensen J (2005). Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline. Cell Signal 17, 1551-1559.
7. Bruusgaard JC, Egner IM, Larsen TK, Dupre-Aucouturier S, Desplanches D & Gundersen K (2012). No change in myonuclear number during muscle unloading and reloading. J Appl Physiol (1985) 113, 290-296.
8. Cardinale JP, Sriramula S, Pariaut R, Guggilam A, Mariappan N, Elks CM & Francis J (2010). HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 56, 437-444.
9. 2-adrenoceptor activation. Am J Physiol Endocrinol Metab 263, E50-E56.
10. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A & Bos JL (1998). Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396, 474-477.
11. Farber E, Sternberg WH & Dunlap CE (1954). Tetrazolium stains for diphosphopyridine nucleotide (DPN) diaphorase and triphosphopyridine nucleotide (TPN) diaphorase in animal tissue. Proc Soc Exp Biol Med 86, 534-537.
12. Goodman CA, Frey JW, Mabrey DM, Jacobs BL, Lincoln HC, You JS & Hornberger TA (2011). The role of skeletal muscle mTOR in the regulation of mechanical load-induced growth. J Physiol 589, 5485-5501.
13. Gosmanov AR, Wong JA & Thomason DB (2002). Duality of G protein-coupled mechanisms for β-adrenergic activation of NKCC activity in skeletal muscle. Am J Physiol Cell Physiol 283, C1025-C1032.
14. Hämäläinen N & Pette D (1993). The histochemical profiles of fast fiber types IIB, IID, and IIA in skeletal muscles of mouse, rat, and rabbit. J Histochem Cytochem 41, 733-743.
15. Hardt SE & Sadoshima J (2002). Glycogen synthase kinase-3β: a novel regulator of cardiac hypertrophy and development. Circ Res 90, 1055-1063.
16. Ishii H, Niioka T & Izumi H (2010). Vagal visceral inputs to the nucleus of the solitary tract: involvement in a parasympathetic reflex vasodilator pathway in the rat masseter muscle. Brain Res 1312, 41-53.
17. Joassard OR, Amirouche A, Gallot YS, Desgeorges MM, Castells J, Durieux AC, Berthon P & Freyssenet DG (2013a). Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscle. Int J Biochem Cell Biol 45, 2444-2455.
18. 2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders. Int J Biochem Cell Biol 45, 2309-2321.
19. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE & Graybiel AM (1998). A family of cAMP-binding proteins that directly activate Rap1. Science 282, 2275-2279.
20. Kiliaridis S, Engström C & Thilander B (1988). Histochemical analysis of masticatory muscle in the growing rat after prolonged alteration in the consistency of the diet. Arch Oral Biol 33, 187-193.
21. 2-adrenoceptors in rat skeletal muscles. Biochem Pharmacol 42, 1783-1789.
22. Lee TJ(2002). Sympathetic modulation of nitrergic neurogenic vasodilation in cerebral arteries. Jpn J Pharmacol 88, 26-31.
23. 2-adrenoceptor/cAMP/PKA/p-CREB signaling pathway. Cell Signal 24, 2297-2306.
24. Liu QS, Wang HF, Sun AK, Huo XP, Liu JL, Ma SH, Peng N & Hu J (2014). A comparative study on inhibition of total astragalus saponins and astragaloside IV on TNFR1-mediated signaling pathways in arterial endothelial cells. PloS One 9, e101504.
25. Liu Y & Schneider MF (2013). Opposing HDAC4 nuclear fluxes due to phosphorylation by β-adrenergic activated protein kinase A or by activity or Epac activated CaMKII in skeletal muscle fibres. J Physiol 591, 3605-3623.
26. Lunde IG, Kvaloy H, Austbo B, Christensen G & Carlson CR (2011). Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT transcription factor isoforms in cardiomyocytes. J Appl Physiol (1985) 111, 1278-1289.
27. Lynch GS & Ryall JG (2008). Role of β-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 88, 729-767.
28. Machholz E, Mulder G, Ruiz C, Corning BF & Pritchett-Corning KR (2012). Manual restraint and common compound administration routes in mice and rats. J Vis Exp 67, e2771.
29. Ohnuki Y, Kawai N, Tanaka E, Langenbach GE, Tanne K & Saeki Y (2009). Effects of increased occlusal vertical dimension on daily activity and myosin heavy chain composition in rat jaw muscle. Arch Oral Biol 54, 783-789.
30. Ohnuki Y & Saeki Y (2008). Jaw-opening muscle contracts more economically than jaw-closing muscle in rat. Arch Oral Biol 53, 193-198.
31. Ohnuki Y, Saeki Y, Yamane A, Kawasaki K & Yanagisawa K (1999). Adaptation of guinea-pig superficial masseter muscle to an increase in occlusal vertical dimension. Arch Oral Biol 44, 329-335.
32. 2-adrenergic signaling in regulation of muscle activity, myosin heavy chain transition, and hypertrophy. J Pharmacol Sci 123, 36-46.
33. Ohnuki Y, Yamada T, Mototani Y, Umeki D, Shiozawa K, Fujita T, Saeki Y & Okumura S (2013b). Effects of protein kinase A on the phosphorylation status and transverse stiffness of cardiac myofibrils. J Pharmacol Sci 123, 279-283.
34. Okumura S, Fujita T, Cai W, Jin M, Namekata I, Mototani Y, Jin H, Ohnuki Y, Tsuneoka Y, Kurotani R, Suita K, Kawakami Y, Hamaguchi S, Abe T, Kiyonari H, Tsunematsu T, Bai Y, Suzuki S, Hidaka Y, Umemura M, Ichikawa Y, Yokoyama U, Sato M, Ishikawa F, Izumi-Nakaseko H, Adachi-Akahane S, Tanaka H & Ishikawa Y (2014). Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. J Clin Invest 124, 2785-2801.
35. Okumura S, Kawabe J, Yatani A, Takagi G, Lee MC, Hong C, Liu J, Takagi I, Sadoshima J, Vatner DE, Vatner SF & Ishikawa Y (2003a). Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ Res 93, 364-371.
36. Okumura S, Suzuki S & Ishikawa Y (2009). New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: effects of targeted disruption of the type 5 adenylyl cyclase gene. J Pharmacol Sci 109, 354-359.
37. Okumura S, Takagi G, Kawabe J, Yang G, Lee MC, Hong C, Liu J, Vatner DE, Sadoshima J, Vatner SF & Ishikawa Y (2003b). Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 100, 9986-9990.
38. Okumura S, Tsunematsu T, Bai Y, Jiao Q, Ono S, Suzuki S, Kurotani R, Sato M, Minamisawa S, Umemura S & Ishikawa Y (2008). Type 5 adenylyl cyclase plays a major role in stabilizing heart rate in response to microgravity induced by parabolic flight. J Appl Physiol (1985) 105, 173-179.
39. Okumura S, Vatner DE, Kurotani R, Bai Y, Gao S, Yuan Z, Iwatsubo K, Ulucan C, Kawabe J, Ghosh K, Vatner SF & Ishikawa Y (2007). Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation 116, 1776-1783.
40. Osuka K, Watanabe Y, Usuda N, Atsuzawa K, Yoshida J & Takayasu M (2009). Modification of endothelial nitric oxide synthase through AMPK after experimental subarachnoid hemorrhage. J Neurotrauma 26, 1157-1165.
41. 2-adrenergic stimulation: implications for hypertrophy, metabolism and circadian rhythm. BMC Genomics 10, e448.
42. Penna F, Bonetto A, Muscaritoli M, Costamagna D, Minero VG, Bonelli G, Rossi Fanelli F, Baccino FM & Costelli P (2010a). Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? Int J Cancer 127, 1706-1717.
43. Penna F, Costamagna D, Fanzani A, Bonelli G, Baccino FM & Costelli P (2010b). Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PloS One 5, e13604.
44. Potthoff MJ, Wu H, Arnold MA, Shelton JM, Backs J, McAnally J, Richardson JA, Bassel-Duby R & Olson EN (2007). Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J Clin Invest 117, 2459-2467.
45. Rommel C, Clarke BA, Zimmermann S, Nuñez L, Rossman R, Reid K, Moelling K, Yancopoulos GD & Glass DJ (1999). Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286, 1738-1741.
46. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, Zeiher AM & Dimmeler S (2002). Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91, 837-844.
47. 2-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am J Physiol Regul Integr Comp Physiol 283, R1386-R1394.
48. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y & Komuro I (2007). p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446, 444-448.
49. Sartorius CA, Lu BD, Acakpo-Satchivi L, Jacobsen RP, Byrnes WC & Leinwand LA (1998). Myosin heavy chains IIa and IId are functionally distinct in the mouse. J Cell Biol 141, 943-953.
50. Shi H, Zeng C, Ricome A, Hannon KM, Grant AL & Gerrard DE (2007). Extracellular signal-regulated kinase pathway is differentially involved in β-agonist-induced hypertrophy in slow and fast muscles. Am J Physiol Cell Physiol 292, C1681-C1689.
51. Suzuki S, Yokoyama U, Abe T, Kiyonari H, Yamashita N, Kato Y, Kurotani R, Sato M, Okumura S & Ishikawa Y (2010). Differential roles of Epac in regulating cell death in neuronal and myocardial cells. J Biol Chem 285, 24248-24259.
52. Turner PV, Brabb T, Pekow C & Vasbinder MA (2011a). Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci 50, 600-613.
53. Turner PV, Pekow C, Vasbinder MA & Brabb T (2011b). Administration of substances to laboratory animals: equipment considerations, vehicle selection, and solute preparation. J Am Assoc Lab Anim Sci 50, 614-627.
54. Umeki D, Ohnuki Y, Mototani Y, Shiozawa K, Fujita T, Nakamura Y, Saeki Y & Okumura S (2013). Effects of chronic Akt/mTOR inhibition by rapamycin on mechanical overload-induced hypertrophy and myosin heavy chain transition in masseter muscle. J Pharmacol Sci 122, 278-288.
55. Wong K, Boheler KR, Bishop J, Petrou M & Yacoub MH (1998). Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features. Cardiovasc Res 37, 115-122.
56. Woo AY & Xiao RP (2012). β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin 33, 335-341.
57. Yu H, He Y, Zhang X, Peng Z, Yang Y, Zhu R, Bai J, Tian Y, Li X, Chen W, Fang D & Wang R (2011). The rat IgGFcβBP and Muc2 C-terminal domains and TFF3 in two intestinal mucus layers bind together by covalent interaction. PloS One 6, e20334.
58. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 98, 1607-1612.